115 results
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
and healthcare industries, including providing corporate finance and mergers and acquisitions advisory services. The Board of Directors requested that Bloom Burton … is an investment banking firm specializing in the life science and healthcare industries. Founded in 2009 in Toronto, Ontario, Bloom Burton is a member
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) and from the UK’s Medicines and Healthcare products Regulatory
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
is regulated as “hazardous” or “toxic” under any Environmental Law.
“Healthcare Laws” means, as applicable: (i) the U.S. Anti-Kickback Statute (42 U.S.C … is, and since January 1, 2018 has been, in material compliance with all applicable Healthcare Laws. Neither the Company nor any Company Subsidiary
6-K
EX-99.1
BLU
Bellus Health Inc
29 Mar 23
Current report (foreign)
5:26pm
Medicines and Healthcare products Regulatory Agency (“MHRA”). In November 2022, we initiated the CALM Phase 3 clinical program, which is composed of two … and Healthcare products Regulatory Agency (“MHRA”).
The CALM Phase 3 clinical program was initiated in the fourth quarter of 2022, with patient enrollment
6-K
EX-99.2
BLU
Bellus Health Inc
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) and from the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA … Agency (“EMA”) and the Medicines and Healthcare products Regulatory Agency (“MHRA”).
The CALM Phase 3 clinical program has been initiated
SUPPL
7ahkqot5khs2q
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
5qhaicaz
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
ujshj
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
3fwqdc11
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
7uuib kcre
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
F-10
mpennq19sw3o qpr
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.2
w0n9v240lo 70aldfv
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
SUPPL
b9wjw4dx6ajw1 ca5
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.2
m58gja8u ry2
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
ls3x4outpfyjxaq
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.1
jx7ub0ie9 dpqcy5f6
1 Jun 22
BELLUS Health to Participate in the Jefferies Healthcare Conference
7:00am
6-K
7ox77mt78fj
1 Jun 22
BELLUS Health to Participate in the Jefferies Healthcare Conference
7:00am
6-K
EX-99.1
c9b20q5
11 May 22
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
5:23pm
6-K
EX-99.2
1m6lb9etp5bvr8gggsdt
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
fhpv zze12bu8psrk
25 Apr 22
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
4:02pm